Multiple primary cancers as a guide to heritability

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1756-1763

  Cybulski, Cezary ^a   Nazarali, Safia ^b   Narod, Steven A ^b  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

cancer predisposition; heredity; multiple primary cancers

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CHEK2 SYNDROME; CHILDHOOD CANCER; COLON CANCER; COWDEN SYNDROME; ENDOMETRIUM CANCER; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FAMILIAL CANCER; FAMILIAL COLON POLYPOSIS; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HEREDITARY DIFFUSE GASTRIC CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HERITABILITY; HUMAN; MELANOMA; MULTIPLE CANCER; MUTYH ASSOCIATED POLYPOSIS; PRIORITY JOURNAL; STOMACH CANCER; THYROID CANCER; VON HIPPEL LINDAU DISEASE;

CANCER PREDISPOSITION; HEREDITY; MULTIPLE PRIMARY CANCERS;

GENES, NEOPLASM; GENETIC TESTING; HUMANS; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY;

EID: 84905743598     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28988     Document Type: Article

References (112)

1. Vogelstein B, Kinzler KW,. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
2. Rahman N,. Realizing the promise of cancer predisposition genes. Nature 2014; 505: 302-8.
3. Lynch HT, Lynch PM, Harris RE,. Minimal genetic findings and their cancer control implications. A family with the cancer family syndrome. JAMA 1978; 240: 535-8.
4. Lynch HT, Guirgis HA, Lynch PM, et al. Familial cancer syndromes: a survey. Cancer 1977; 39: 1867-81. Review.
5. Hansen MF, Koufos A, Gallie BL, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci USA 1985; 82: 6216-20.
6. Li FP, Melvin KE, Tashjian AH, Jr, et al. Familial medullary thyroid carcinoma and pheochromocytoma: epidemiologic investigations. J Natl Cancer Inst 1974; 52: 285-7.
7. Melmon KL, Rosen SW,. Lindau's disease. Review of the literature and study of a large kindred. Am J Med 1964; 36: 595-617.
8. Go RC, King MC, Bailey-Wilson J, et al. Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregation analysis. J Natl Cancer Inst 1983; 71: 455-61.
9. Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994; 96: 516-20.
10. Pal T, Hamel N, Vesprini D, et al. Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications. Fam Cancer 2001; 1: 17-24.
11. Verhage BA, Aben KK, Witjes JA, et al. Site-specific familial aggregation of prostate cancer. Int J Cancer 2004; 109: 611-7.
12. Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, et al. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995; 87: 991-6.
13. Xu J, Dimitrov L, Chang BL, et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005; 77: 219-29.
14. Eng C,. Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 2000; 37: 828-30.
15. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105: 1607-16.
16. Cybulski C, Gõrski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75: 1131-5.
17. Levy-Lahad E, Catane R, Eisenberg S, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60: 1059-67.
18. Akbari M, Donenberg T, Lunn J, et al. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet 2014; 85: 64-7.
19. Tonin PN, Mes-Masson AM, Futreal PA,. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet 1998; 63: 1341-51.
20. Gõrski B, Jakubowska A, Huzarski T, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004; 110: 683-6.
21. Cybulski C, Wokołorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011; 29: 3747-52.
22. Piccione M, Fragapane T, Antona V, et al. PTEN hamartoma tumor syndromes in childhood: description of two cases and a proposal for follow-up protocol. Am J Med Genet A 2013; 161A: 2902-8.
23. Maher ER, Neumann HP, Richard S,. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 2011; 19: 617-23.
24. Lynch HT, de la Chapelle A,. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801-18.
25. Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 1995; 273: 535-41.
26. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
27. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
28. King MC, Marks JH, Mandell JB,. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-6.
29. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-8.
30. Chen S, Parmigiani G,. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33.
31. Lubinski J, Huzarski T, Byrski T, et al. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer 2012; 131: 229-34.
32. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: the Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-89.
33. Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000; 83: 1301-8.
34. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8: 3776-81.
35. Menkiszak J, Gronwald J, Gõrski B, et al. Hereditary ovarian cancer in Poland. Int J Cancer 2003; 106: 942-5.
36. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathological features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283: 2260-5.
37. Sun CC, Lenoir G, Lynch H, et al. In-situ breast cancer and BRCA1. Lancet 1996; 348: 408.
38. Lakhani SR,. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1999; 1: 31-5.
39. Lubiński J, Gõrski B, Huzarski T, et al. BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 2006; 99: 71-6.
40. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000; 6: 782-9.
41. Brownstein MH, Wolf M, Bikowski JB,. Cowden's disease: a cutaneous marker of breast cancer. Cancer 1978; 41: 2393-8.
42. Starink TM, van der Veen JP, Arwert F, et al. The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986; 29: 222-33.
43. Tan MH, Mester J, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18: 400-7.
44. Schrager CA, Schneider D, Gruener AC,. Clinical and pathological features of breast disease in Cowden's syndrome: an under-recognized syndrome with an increased risk of breast cancer. Hum Pathol 1998; 29: 47-53.
45. Ngeow J, Mester J, Rybicki LA, et al. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endo Metab 2011; 96: E2063-71.
46. Li FP, Fraumeni JF, Jr,. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969; 71: 747-52.
47. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
48. Lustbader ED, Williams WR, Bondy ML, et al. Segregation analysis of cancer in families of childhood soft tissue sarcoma patients. Am J Hum Genet 1992; 51: 344-56.
49. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li-Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009b; 27: 1250-6.
50. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li Fraumeni syndrome. J Natl Cancer Inst 1998; 90: 606-11.
51. Matsuoka S, Huang M, Elledge SJ,. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 1998; 282: 1893-7.
52. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286: 2528-31.
53. Evans DG, Birch JM, Narod SA,. Is CHEK2 a cause of the Li-Fraumeni syndrome? J Med Genet 2008; 45: 63-4.
54. Ruijs MW, Broeks A, Menko FH, et al. The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype. Hered Cancer Clin Pract 2009; 7: 4.
55. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-9.
56. Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004; 75: 1131-5.
57. Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003; 72: 270-80.
58. Seppala EH, Ikonen T, Mononen N, et al. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003; 89: 1966-70.
59. Kilpivaara O, Alhopuro P, Vahteristo P, et al. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 2006; 43: e34.
60. Cybulski C, Wokołorczyk D, Kładny J, et al. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 2007; 15: 237-41.
61. Cybulski C, Wokołorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011; 29: 3747-52.
62. Teodorczyk U, Cybulski C, Wokołorczyk D, et al. The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer 2013; 12: 473-8.
63. Meijers-Heijboer H, Wijnen J, Vasen H, et al. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003; 72: 1308-14.
64. Cybulski C, Gliniewicz B, Sikorski A, et al. Epistatic relationship between the cancer susceptibility genes CHEK2 and p27. Cancer Epidemiol Biomarkers Prev 2007; 16: 572-6.
65. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8: 15-21.
66. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16 (INK4) mutations. New Eng J Med 1995; 333: 970-4.
67. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006; 66: 9818-28.
68. Parker JF, Florell SR, Alexander A, et al. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 2003; 139: 1019-25.
69. de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008; 14: 7151-7.
70. Whelan AJ, Bartsch D, Goodfellow PJ,. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995; 333: 975-7.
71. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013; 62: 812-23.
72. Papadopoulos N, Nicolaides NC, Wei YF,. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263: 1625-9.
73. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993; 75: 1215-25.
74. Akiyama Y, Sato H, Yamada T, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997; 57: 3920-3.
75. Nicolaides NC, Papadopoulos N, Liu B, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371: 75-80.
76. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
77. Bellizzi AM, Frankel WL,. Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol 2009; 16: 405-17.
78. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009; 48: 737-44.
79. Nagasaka T, Rhees J, Kloor M, et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res 2010; 70: 3098-108.
80. Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001; 91: 2417-22.
81. Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001; 69: 780-90.
82. de Leeuw WJ, Dierssen J, Vasen HF, et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 2000; 192: 328-35.
83. Petersen GM, Slack J, Nakamura Y,. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 1991; 100: 1658-64.
84. Bussey HJR., Familial polyposis coli. Baltimore, MD: Johns Hopkins University Press, 1975.
85. Giardiello FM, Krush AJ, Petersen GM, et al. Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation. Gastroenterology 1994; 106: 1542-7.
86. Rozen P, Samuel Z, Shomrat R, et al. Notable intrafamilial phenotypic variability in a kindred with familial adenomatous polyposis and an APC mutation in exon 9. Gut 1999; 45: 829-33.
87. Nielsen M, Hes FJ, Nagengast FM, et al. Germline mutations in APC and MUTYH are responsible for the majority of families with attenuated familial adenomatous polyposis. Clin Genet 2007; 71: 427-33.
88. Wallace MH, Phillips RK,. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 1998; 85: 742-50.
89. Kadmon M, Tandara A, Herfarth C,. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis 2001; 16: 63-75.
90. Ruys AT, Alderlieste YA, Gouma DJ, et al. Jejunal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2010; 8: 731-3.
91. Aretz S, Stienen D, Friedrichs N, et al. Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum Mutat 2007; 28: 985-92.
92. Al Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C - >T:A mutations in colorectal tumors. Nat Genet 2002; 30: 227-32.
93. Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ- line mutations in MYH. N Engl J Med 2003; 348: 791-9.
94. Boparai KS, Dekker E, Van Eeden S, et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 2008; 135: 2014-8.
95. O'Shea AM, Cleary SP, Croitoru MA, et al. Pathological features of colorectal carcinomas in MYH-associated polyposis. Histopathology 2008; 53: 184-94.
96. Nielsen M, Joerink-van de Beld MC, Jones N, et al. Analysis of MUTYH genotypes and colorectal phenotypes in patients with MUTYH-associated polyposis. Gastroenterology 2009; 136: 471-6.
97. Abdelmaksoud-Dammak R, Miladi-Abdennadher I, Amouri A, et al. High prevalence of the c.1227-1228dup (p.Glu410GlyfsX43) mutation in Tunisian families affected with MUTYH-associated-polyposis. Fam Cancer 2012; 11: 503-8.
98. Lubbe SJ, Di Bernardo MC, Chandler IP, et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 2009; 27: 3975-80.
99. Lipton L, Tomlinson I,. The genetics of FAP and FAP-like syndromes. Fam Cancer 2006; 5: 221-6.
100. Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009; 137: 1976-85.
101. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-5.
102. Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 1998; 58: 4086-9.
103. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 2007; 297: 2360-72.
104. Pharoah PD, Guilford P, Caldas C,. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001; 121: 1348-53.
105. Maher ER, Iselius L, Yates JR, et al. von Hippel-Lindau disease: a genetic study. J Med Genet 1991; 28: 443-7.
106. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-20.
107. Cybulski C, Krzystolik K, Maher ER, et al. Long polymerase chain reaction in detection of germline deletions in the von Hippel-Lindau tumour suppressor gene. Hum Genet 1999; 105: 333-6.
108. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998; 12: 417-23.
109. Maher ER, Neumann HP, Richard S,. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 2011; 19: 617-23.
110. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 1876-81.
111. Narod SA, Pal T, Graham T, et al. Tamoxifen and risk of endometrial cancer. Lancet 2001; 357: 65-6.
112. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37.